US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

265.02

+2.030.77%

Pre-market: 265.020.00000.00%04:00 EDT

Volume:42.25K

Turnover:11.21M

Market Cap:2.88B

PE:31.01

High:266.64

Open:263.60

Low:263.60

Close:262.99

52wk High:274.99

52wk Low:173.98

Shares:10.85M

Float Shares:10.85M

Volume Ratio:1.48

T/O Rate:0.39%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.03

PE(LYR):7.02

Loading ...

Overview Company News Filings

CareDx Q2 Revenue Beats Estimates; Outlook Lifted

Veracyte Q2 Revenue USD 150.3 Million Vs. IBES Estimate USD 144.6 Million

Veracyte Outlook 2026 - Continues to Expect Adjusted Ebitda Margin to be Greater than 26%

THOMSON REUTERS

Veracyte Q2 EPS USD 0.31

THOMSON REUTERS

Veracyte Outlook FY Revenue Growth 14-15%

THOMSON REUTERS

Veracyte Q2 Gross Margin 72%

THOMSON REUTERS

Veracyte: Outlook 2026 Raises Testing Revenue Guidance to $576 Million to $582 Million

THOMSON REUTERS

Veracyte Announces Second Quarter 2026 Financial Results

Disc Medicine Posts Smaller-than-expected Q2 Net Loss

Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth

Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $161 from $150

THOMSON REUTERS

Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know

Benzinga Earnings

NeoGenomics (NEO) Stock Rallies As Profit Returns And Margins Improve

Simply Wall St.

Corcept Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Corcept Therapeutics Q2 EPS USD 0.36

Corcept Q2 FY26 Net Income Rises to $43 Million; Revenue Climbs 32% to $256.1 Million

Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook

Update: NeoGenomics Shares Rise After Q2 Beat

MT Newswires Live

Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says

MT Newswires Live

Neogenomics Inc : Needham Raises Target Price to $19 from $15

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/FBT/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":265.02,"timestamp":1789588800000,"preClose":262.99,"halted":0,"volume":42247,"hourTrading":{"tag":"盘前","latestPrice":265.02,"preClose":265.02,"latestTime":"04:00 EDT","volume":1,"amount":265.02,"timestamp":1789632002243,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007718924673941871,"floatShares":10850002,"shares":10850002,"eps":8.545272,"marketStatus":"Pre-Mkt","change":2.03,"latestTime":"09-17 04:43:27 EDT","open":263.6,"high":266.64,"low":263.6,"amount":11212835.415800001,"amplitude":0.011559,"askPrice":272.25,"askSize":200,"bidPrice":259.31,"bidSize":200,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":265.02,"sharesOutstanding":11450002,"nav":263.09,"aum":2867681526.18,"bidAskSpread":0.001046,"preHourTrading":{"tag":"盘前","latestPrice":265.02,"preClose":265.02,"latestTime":"04:00 EDT","volume":1,"amount":265.02,"timestamp":1789632002243,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":265.02,"preClose":265.02,"latestTime":"19:30 EDT","volume":17,"amount":4505.34,"timestamp":1789601405208,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4797444506447395,"impliedVol":0.1995,"impliedVolPercentile":0.344},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10850002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":1.4797444506447395,"shares":10850002,"dividePrice":0,"high":266.64,"amplitude":0.011559,"preClose":262.99,"low":263.6,"week52Low":173.975,"pbRate":"1.03","psRate":"693.68","week52High":274.99,"institutionHeld":0,"latestPrice":265.02,"eps":8.545272,"divideRate":0,"volume":42247,"delay":0,"ttmEps":8.545272,"open":263.6,"prevYearClose":206.52,"prevWeekClose":261.85,"prevMonthClose":267.15,"prevQuarterClose":247.89,"fiveDayClose":265.563,"twentyDayClose":260.7392,"sixtyDayClose":229.79},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655383003","title":"CareDx Q2 Revenue Beats Estimates; Outlook Lifted","url":"https://stock-news.laohu8.com/highlight/detail?id=2655383003","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655383003?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:10","pubTimestamp":1785442216,"startTime":"0","endTime":"0","summary":"CareDx Q2 revenue beats estimates; outlook liftedOverviewPrecision medicine diagnostics firm's Q2 revenue rose 52% yr/yr, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectationsCompa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W1H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","LU0012050646.USD","LU0006061336.USD","BK4139","ADPT","LH","LU0251142724.SGD","BK4121","LU0048573561.USD","BK4196","NEO","LU2237438978.USD","CDNA","BK4585","LU1059921491.USD","BK4588","LU0106261612.USD","BK4550","LU0251131958.USD","HELX","LU0742534661.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655383055","title":"Veracyte Q2 Revenue USD 150.3 Million Vs. IBES Estimate USD 144.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655383055","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655383055?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:06","pubTimestamp":1785441963,"startTime":"0","endTime":"0","summary":"BRIEF-Veracyte Q2 Revenue USD 150.3 Million Vs. IBES Estimate USD 144.6 MillionJul 30 (Reuters) - Veracyte Q2 net income USD 25.5 million.Q2 gross margin 72%Q2 adjusted operating expenses USD 70 millionoutlook FY revenue USD 590-596 million vs. IBES estimate USD 586.4 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLXJWB2R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","FBT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655838603","title":"Veracyte Outlook 2026 - Continues to Expect Adjusted Ebitda Margin to be Greater than 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655838603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655838603?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:05","pubTimestamp":1785441904,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLXJWB2R0:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655386099","title":"Veracyte Q2 EPS USD 0.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2655386099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655386099?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:05","pubTimestamp":1785441904,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLXJWB2R0:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","BK4139","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655386087","title":"Veracyte Outlook FY Revenue Growth 14-15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655386087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655386087?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:05","pubTimestamp":1785441904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLXJWB2R0:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VCYT","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655383193","title":"Veracyte Q2 Gross Margin 72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655383193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655383193?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:05","pubTimestamp":1785441904,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLXJWB2R0:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","VCYT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655084386","title":"Veracyte: Outlook 2026 Raises Testing Revenue Guidance to $576 Million to $582 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655084386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655084386?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:05","pubTimestamp":1785441904,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLXJWB2R0:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VCYT","FBT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655385117","title":"Veracyte Announces Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2655385117","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655385117?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:05","pubTimestamp":1785441900,"startTime":"0","endTime":"0","summary":"Grew total revenue to$150.3million and testing revenue to $145.7million, representing increases of 15% and 19% year-over-year, respectivelyConference call and webcast today at 4:30 p.m. ET SOUTH SAN F","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3336432/0/en/Veracyte-Announces-Second-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","FBT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655287772","title":"Disc Medicine Posts Smaller-than-expected Q2 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2655287772","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655287772?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:39","pubTimestamp":1785415190,"startTime":"0","endTime":"0","summary":"Disc Medicine posts smaller-than-expected Q2 net lossOverviewUS biopharma firm's Q2 net loss and operating income both beat analyst expectationsQ2 loss per share was better than expectedOperating expe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W0T2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","FBT","LU0053671581.USD","CORT","AVXL","BK4532","LU1559883803.SGD","PSCH","BK4139","BK4007","IRON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655987926","title":"Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2655987926","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655987926?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:18","pubTimestamp":1785410307,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals Q2 revenue beats on Voquezna prescription growthOverviewUS biopharma firm's Q2 revenue rose 88% yr/yr, beating analyst expectationsQ2 operating expenses fell 33% yr/yr due to l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W0KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU1559883803.SGD","LU0234570918.USD","BK4588","CORT","LU0320765992.SGD","BIIB","IE00B19Z9P08.USD","BK4532","PHAT","LU0566484027.USD","BK4007","LU0889565916.HKD","LU0109394709.USD","PSCH","BK4585","BK4139","IE00B894F039.SGD","FBT","PBE","IE00B19Z9Z06.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655282910","title":"Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $161 from $150","url":"https://stock-news.laohu8.com/highlight/detail?id=2655282910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655282910?lang=en_us&edition=fundamental","pubTime":"2026-07-30 15:55","pubTimestamp":1785398154,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1F1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","BK4007","LU1559883803.SGD","LU0566484027.USD","FBT","CORT","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655782580","title":"Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782580","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655782580?lang=en_us&edition=fundamental","pubTime":"2026-07-30 14:48","pubTimestamp":1785394133,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidance boosted investor confidence.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/07/60787510/corcept-therapeutics-shares-surge-after-hours-q2-results-raised-guidance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ODDS","RSI","LU0566484027.USD","ODDZ","CORT","BETZ","BK4007","NUWE","PSCH","LU1559883803.SGD","BK4150","BK4532","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655486328","title":"NeoGenomics (NEO) Stock Rallies As Profit Returns And Margins Improve","url":"https://stock-news.laohu8.com/highlight/detail?id=2655486328","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655486328?lang=en_us&edition=fundamental","pubTime":"2026-07-30 07:23","pubTimestamp":1785367402,"startTime":"0","endTime":"0","summary":"NeoGenomics came into this print as an expensive growth story in cancer diagnostics, with a rich P/S multiple and a long stretch of losses. The stock jumped about 14% to US$15.27 today, which indicates investors liked what they saw. The key focus is margin and profit repair. NeoGenomics moved from a loss in Q1 to a modest profit in Q2 and lifted adjusted EBITDA, helped by higher average price per test and its Lab of the Future efficiency work. The rest of the earnings detail supports that...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/neogenomics-neo-stock-rallies-as-profit-returns-and-margins","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/neogenomics-neo-stock-rallies-as-profit-returns-and-margins","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0012050646.USD","LU0106261612.USD","BK4121","BK4196","FBT","NEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655103338","title":"Corcept Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2655103338","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655103338?lang=en_us&edition=fundamental","pubTime":"2026-07-30 06:40","pubTimestamp":1785364847,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryCorcept Therapeutics IncCORT.OQreported quarterly adjusted earnings of 36 cents per share for the quarter ended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL8N43V3R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","BK4532","BK4007","LU1559883803.SGD","PSCH","CORT","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816067","title":"Corcept Therapeutics Q2 EPS USD 0.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816067","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816067?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:16","pubTimestamp":1785356177,"startTime":"0","endTime":"0","summary":"Jul 29 (Reuters) - Corcept Therapeutics Q2 revenue USD 256.147 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 29-JUL-202615:42:50 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nRSD73tzLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","CORT","BK4007","FBT","BK4532","LU1559883803.SGD","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655581677","title":"Corcept Q2 FY26 Net Income Rises to $43 Million; Revenue Climbs 32% to $256.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655581677","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655581677?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:15","pubTimestamp":1785356143,"startTime":"0","endTime":"0","summary":"Corcept Q2 FY26 net income rises to $43 million; revenue climbs 32% to $256.1 millionCorcept Q2 revenue rose 32% to USD 256.1 million, with Korlym and authorized generic at USD 208.6 million and Lifyo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL3dG2zq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","LU1559883803.SGD","FBT","BK4532","BK4007","PSCH","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655162788","title":"Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2655162788","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655162788?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:13","pubTimestamp":1785355980,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Q2 revenue estimates, raises 2026 outlookOverviewU.S. biopharma firm's Q2 revenue rose 32% yr/yr, beating analyst expectationsNet income for Q2 increased to $43.0 mln from $35.1 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL1N43V1C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0234570918.USD","FBT","BK4139","BK4007","CORT","PSCH","IE00B19Z9Z06.USD","INCY","IDNA","BK4588","BK4550","LU1559883803.SGD","IE00B19Z9P08.USD","BMED","PBE","LU0566484027.USD","LU0889565916.HKD","BK4585","LU0109394709.USD","IE00B894F039.SGD","BK4532","BIIB","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655981330","title":"Update: NeoGenomics Shares Rise After Q2 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2655981330","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655981330?lang=en_us&edition=fundamental","pubTime":"2026-07-30 02:50","pubTimestamp":1785351016,"startTime":"0","endTime":"0","summary":"NeoGenomics  shares were up over 15% in Wednesday trading following its better-than-expected Q2 results.Late Tuesday, the company reported Q2 adjusted earnings of $0.05 per diluted share, up from $0.03 a year earlier.Analysts polled by FactSet expected $0.03.Revenue for the quarter ended June 30 was $201.7 million, up from 181.3 million a year earlier.Analysts expected $196.9 million.The company said it now expects 2026 revenue of $802 million to $806 million, up from its prior range of $797 million to $803 million. Analysts expect $800.4 million.Price: 15.51, Change: +2.11, Percent Change: +15.75","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEO","BK4196","LU0106261612.USD","BK4121","FBT","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655926538","title":"Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655926538","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655926538?lang=en_us&edition=fundamental","pubTime":"2026-07-29 23:53","pubTimestamp":1785340439,"startTime":"0","endTime":"0","summary":"Alkermes'  base business supported the company's Q2 beat, while its orexin pipeline serves as a potential catalyst for future revenue growth, RBC Capital Markets said in a Tuesday note.The company reported a breakeven in Q2, compared with earnings of $0.52 per share a year earlier, and revenue of $496 million, up from $390.7 million. For 2026, Alkermes reiterated its total revenue guidance of $1.73 billion to $1.84 billion.Alkermes' core business drove the quarter's revenue beat, with recent highlights like less generic threat for Vivitrol and expanded access for Lybalvi, RBC said. The quarter also said one-time benefits from patient mix favorability, Lumryz inventory and Consta manufacturing, the brokerage added.Looking forward, investor focus is shifting to the company's orexin pipeline expansion into other indications, which could help pave the way for Alkermes's revenue to exceed $5 billion, RBC noted.RBC has an outperform rating and $56 price target on Alkermes.Price: 48.40, Chang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBRN","FBT","PSCH","BK4139","ALKS","PSIL","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655649208","title":"Neogenomics Inc : Needham Raises Target Price to $19 from $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2655649208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655649208?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:07","pubTimestamp":1785323273,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V1F4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEO","BK4121","LU0106261612.USD","LU0012050646.USD","BK4196","FBT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}